Teva Makes Concessions in EU Review of Bid for Allergan Unit

  • EU extends deadline to rule on the deal until March 10
  • Concessions may allow companies win early approval for deal

Teva Pharmaceutical Industries Ltd. made concessions to European Union regulators for its takeover of Allergan Plc’s generics unit, potentially averting a lengthy probe into the $40.5 billion tie-up.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.